Gilead stock falls after disappointing early trial results for highly anticipated coronavirus treatment
Stock trading was briefly halted Thursday for California-based Gilead Sciences, after a draft report said the company’s experimental coronavirus treatment disappointed in a recent drug trial. Shares continued to slump, even after the biotech company moved quickly to dispute the findings of the World Health